PhRMA Letter to HRSA and HHS Regarding Duplicate Discounting in 340B

PhRMA submitted a letter to the Health Resources and Services Administration (HRSA) and U.S. Department of Health and Human Services (HHS) expressing serious concerns regarding HRSA’s recent public statements about use of a rebate option to offer statutory 340B ceiling prices to covered entities.

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.